Diffusion into Use of Exenatide for Glucose Control in Diabetes Mellitus: A Retrospective Cohort Study of a New Therapy

Clinical Therapeutics

Volumn 29, Issue 8, 2007, Pages 1784-1794

  Segal, Jodi B ^a   Dy, Sydney M ^b   Millman, E Anne ^b   Herbert, Robert ^b   Bass, Eric B ^a,b   Wu, Albert ^a,b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

diabetes mellitus; exenatide; incretin mimetic; therapeutics

Indexed keywords

EXENDIN 4; GLITAZONE DERIVATIVE; GLUCOSE; INSULIN; METFORMIN; SULFONYLUREA;

ADULT; ARTICLE; CLINICAL FEATURE; COHORT ANALYSIS; DIABETES MELLITUS; DIABETIC PATIENT; DRUG APPROVAL; DRUG INDICATION; DRUG USE; FEMALE; FOOD AND DRUG ADMINISTRATION; HOSPITAL PATIENT; HUMAN; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; OBESITY; OFF LABEL DRUG USE; OUTPATIENT CARE; PHARMACY; PRESCRIPTION; RETROSPECTIVE STUDY;

ADULT; BLOOD GLUCOSE; COHORT STUDIES; DIABETES MELLITUS; DIFFUSION OF INNOVATION; DRUG LABELING; DRUG THERAPY, COMBINATION; DRUG UTILIZATION REVIEW; FEMALE; GUIDELINE ADHERENCE; HUMANS; HYPOGLYCEMIC AGENTS; INSURANCE, PHARMACEUTICAL SERVICES; MALE; MIDDLE AGED; OBESITY; PEPTIDES; PRACTICE GUIDELINES AS TOPIC; PRESCRIPTIONS, DRUG; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION; VENOMS;

EID: 34848921129     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2007.08.021     Document Type: Article

References (20)

1. National Diabetes Surveillance System, National Center for Chronic Disease Prevention and Health Promotion. Prevalence of diabetes.
2. Available at:. http://www.cdc.gov/diabetes/statistics/prev/national/index.htm Accessed May 10, 2005.
3. Meyer RJ. Approval letter for Byetta.
4. Available at:. http://www.fda.gov/cder/foi/appletter/2005/0217731tr.pdf Accessed April 28, 2005.
5. Ratner R., Maggs D., Nielsen L., et al. Long-term effects of exenatide therapy over 82 weeks on glycaemic control and weight in over-weight metformin-treated patients with type 2 diabetes mellitus. Diabetes Obes Metab 8 (2006) 419-428
6. Buse J., Henry R., Han J., et al., for the Exenatide-113 Clinical Study Group. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 27 (2004) 2628-2635
7. DeFronzo I., Ratner R., Han J., et al. Effects ofexenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 28 (2005) 1092-1100
8. Fineman M., Bicsak T., Shen L., et al. Effect on glycemic control of exenatide (synthetic exendin-4) additive to existing metformin and/or sulfonylurea treatment in patients with type 2 diabetes. Diabetes Care 26 (2003) 2370-2377
9. Fineman M., Shen L., Taylor K., et al. Effectiveness of progressive dose-escalation ofexenatide (exendin-4) in reducing dose-limiting side effects in subjects with type 2 diabetes. Diabetes Metab Res Rev 20 (2004) 411-417
10. Kendall D., Riddle M., Rosenstock J., et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 28 (2005) 1083-1091
11. Poon T., Nelson P., Shen L., et al. Exenatide improves glycemic control and reduces body weight in subjects with type 2 diabetes: A dose-ranging study. Diabetes Technol Ther 7 (2005) 467-477
12. Heine R., Van Gaal L., Johns D., et al., for the GWAA Study Group. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: A randomized trial. Ann Intern Med 143 (2005) 559-569
13. Nauck M., Duran S., Kim D., et al. A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: A non-inferiority study. Diabetologia 50 (2007) 259-267
14. Hebert P., Geiss L., Tierney E., et al. Identifying persons with diabetes using Medicare claims data. AmJ Med Qual 14 (1999) 270-277
15. Miller D., Safford M., and Pogach L. Who has diabetes? Best estimates of diabetes prevalence in the Department of Veterans Affairs based on computerized patient data. Diabetes Care 27 Suppl 2 (2004) B10-B21
16. The Johns Hopkins University ACG Case-Mix System. Release notes v8.0.
17. Available at:. http://www.acg.jhsph.edu/ACGDocuments/Software%20Documentation/ACG.htm Accessed May 10, 2005.
18. Hampton T. Experts weigh in on promotion, prescription of off-label drugs. JAMA 297 (2007) 683-684
19. Radley D., Finkelstein S., and Stafford R. Off-label prescribing among office-based physicians. Arch Intern Med 166 (2006) 1021-1026
20. Segal JB, Griswold M, Achy-Brou A, et al. Using propensity scores subclassification to estimate effects of longitudinal treatments: An example using a new diabetes medication. Med Care. In press.